Previous Article | Next Article 
Molecular and Cellular Biology, December 1999, p. 8686-8693, Vol. 19, No. 12
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Disruption of muREC2/RAD51L1 in Mice
Results in Early Embryonic Lethality Which Can Be Partially
Rescued in a p53
/
Background
Zhigang
Shu,
Sheryl
Smith,
Lijuan
Wang,
Michael C.
Rice, and
Eric B.
Kmiec*
Department of Biological Sciences, University
of Delaware, Newark, Delaware 19716
Received 12 March 1999/Returned for modification 17 April
1999/Accepted 16 September 1999
 |
ABSTRACT |
muREC2/RAD51L1 is a radiation-inducible gene that
regulates cell cycle progression. To elucidate the biological
function of muREC2/RAD51L1, the gene was disrupted in
embryonic stem cells by homologous recombination. Mice heterozygous for
muREC2/RAD51L1 appear normal and fertile; however, no
homozygous pups were born after interbreeding of heterozygous mice.
Timed pregnancy studies showed that homozygous mutant embryos were
severely retarded in growth as early as ca. 5 days gestation (E5.5) and
were completely resorbed by E8.5. Mutant blastocyst outgrowth was also
severely impaired in a double-knockout embryo, but embryonic
development did progress further in a p53-null background.
These results suggest that muREC2/RAD51L1 plays a role in cell
proliferation and early embryonic development, perhaps through
interaction with p53.
 |
INTRODUCTION |
In the past few years, an increasing
number of genes in the recA/RAD51 recombination-repair
family have been cloned, including REC2/RAD51L1,
RAD51C, RAD51D, R51H3,
XRCC2, and XRCC3 (1, 3, 4, 24, 25, 31,
32). Among them, REC2/RAD51L1, which was first cloned
in our lab and subsequently at two other labs, encodes a 350-amino-acid
protein exhibiting significant homology to the Escherichia coli
RECA and Ustilago maydis REC2 and RAD51 genes (25, 26). The regions of similarity include the
nucleotide-binding A and B motifs and a DNA binding domain.
Overexpression of hREC2/RAD51L1 in Chinese hamster ovary
(CHO) cells causes a G1 delay in the cell cycle and
hypersensitivity to UV irradiation (10). Overexpression of
hREC2/RAD51L1 in T cells of transgenic mice results in
partial blockage of T-cell differentiation and hypersensitivity of T
cells to ionizing radiation (27a).
Although the human Rec2/Rad51L1 protein has not been shown to catalyze
recombinase reactions such as DNA pairing and strand transfer, amino
acid alignment classifies the gene as a RAD51 ortholog. Some
similarities in function have been noted, however. The
REC2/RAD51L1 gene is induced by both ionizing radiation
(25) and UV radiation (22). The hsRad51 protein
appears to be recruited to the nucleus in response to DNA damage
(8) and has been shown to interact with p53 directly,
suggesting a role in cell cycle regulation and perhaps apoptosis
(2, 28). Finally, disruption of both the muRAD51
gene and the muREC2/RAD51L1 gene results in early embryonic
lethality (16, 34) (see below). The role of muRec2/Rad51L1
in DNA repair may not involve direct interaction with the damaged site.
Thus far, we have been unable to demonstrate a significant level of DNA
recognition by this protein (24a), and no ATP-hydrolytic
activity has been observed (6a). Furthermore, recent results
indicate that this gene may form fusion products upon translocation
with an HMGC1 gene in leiomyoma. Potentiating the response
to DNA damage may involve an indirect association with the proteins
that regulate the cell cycle. Thus, in terms of DNA repair, the
properties of this homolog of Rad51 are likely to be very different
from those of the prototype protein.
To investigate the biological function of muREC2/RAD51L1 and
create a mouse model to study DNA repair mechanisms, we disrupted muREC2/RAD51L1 in embryonic stem (ES) cells via homologous
recombination. These experiments resulted in the creation of mice
bearing a single allelic copy of the mREC2/RAD51L1 gene. We
were unable to obtain a homozygous knockout mouse because the targeting
process resulted in early embryonic lethality. Heterozygous mice appear
normal after 12 months, while homozygous mutants die during early
embryonic development. Analysis of mutant embryos in vivo and in vitro
indicated that REC2/RAD51L1 is essential for cell
proliferation. Although breeding of
REC2/RAD51L1-heterozygous mice with p53-knockout
mice failed to generate double-knockout pups, the double-mutant embryos survived longer, indicating a partial rescue by p53. In this
report, we outline the details of our efforts.
 |
MATERIALS AND METHODS |
Construction of targeting vectors.
A human
REC2/RAD51L1 cDNA probe (an XbaI-KpnI
fragment from the pT3T7 plasmid) was used to screen a 129/sv mouse
genomic library (Stratagene), and a 16-kb fragment containing exons and
2 was isolated. Genomic subfragments from the fragment were subcloned into pBluescript SK(+) (Stratagene), and the restriction map and the
intron-exon boundaries were determined by direct sequencing and
restriction site mapping. A 3.6-kb EcoRI fragment containing exon 2 was used to make the targeting vectors. A dicistronic
-galactosidase-neomycin (
-geo) cassette containing the
picornavirus internal ribosome entry sequence (IRES) and a splice
receptor (kindly provided by P. Mountford, Agricultural and Food
Research Council Centre for Genome Research, University of Edinburgh,
Edinburgh, Scotland) was inserted into a unique StuI site on
exon 2 (21). The insertion and correct orientation were
confirmed by direct sequencing. To construct the hygromycin targeting
vector, a phosphoglycerate kinase-hygromycin cassette (kindly provided
by S. M. A. Swagemakers, Erasmus University, Rotterdam, The
Netherlands) was inserted at the same StuI site on exon 2. The vector was linearized with XhoI before electroporation
into ES cells.
Transfection and analysis of ES cells.
J1 ES cells were
cultured as described elsewhere (15), and 25 µg of
linearized IRES targeting vector was electroporated into 2 × 107 ES cells. G418 (Gibco-BRL) was added 24 h later to
a final concentration of 250 µg/ml (active substance). After 7 to 8 days of selection, individual clones were picked and expanded. DNA was
prepared and analyzed by Southern blotting with probe B, which
hybridizes outside of the targeting vector (Fig.
1). Correct integration was confirmed by
using probe A, which localizes on the 5' side of the gene. Single
integration events were tested by probing the same blots with a
neomycin resistance gene (neo) probe.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 1.
Targeted disruption of the muREC2/RAD51L1
gene. (A) Genomic structure of muREC2/RAD51L1 and targeting
vectors. Exons 1 and 2 (closed boxes) encode the nuclear localization
signal and part of the putative zinc finger motif. The IRES targeting
vector was constructed by inserting an IRES- -geo cassette into exon
2 at the StuI site (21). A hygromycin targeting
vector was also constructed by inserting a PGK-hygromycin cassette
(pgk-hyg) into the same StuI site to target the other allele
(5). The insertion and correct orientation of the cassette
were confirmed by direct sequencing. Abbreviations for restriction
sites are as follows: X, XbaI; O, EcoRV; H,
HindIII; P, PstI; E, EcoRI; S,
StuI; and B, BamHI. (B) Targeted allele and
expected size determined by Southern blotting. Upon XbaI
digestion, probe A generates one 16-kb wild-type band and a 13-kb
mutant band. Probe B generates one 16-kb wild-type band and a 3-kb
mutant band. Arrowheads indicate primers used for genotyping. (C)
Southern blot analysis of targeted ES cell clones. DNA from ES cells
was digested with XbaI. Initial screening was performed with
probe B and then confirmed by using probe A. (D) Semiquantitative
RT-PCR of mouse thymus RNA. Total RNA were extracted from the thymuses
of a muREC2/RAD51L1-heterozygous mouse and a wild-type mouse
(6 to 8 weeks old). RT-PCR was performed with a pair of primers
amplifying the entire muREC2/RAD51L1 cDNA (see Materials and
Methods). The level of expression in heterozygous mice was roughly 50%
of that in the wild-type mouse. Actin was used as an internal control
for normalization.
|
|
Generation of chimeric mice and
REC2/RAD51L1-heterozygous mice.
Two independent clones
heterozygous for REC2/RAD51L1 were microinjected into
C57BL/6 blastocysts at the Thomas Jefferson University Transgenic
Facility by standard procedures (12). Integrated blastocysts
were implanted into pseudopregnant (CBA × C57BL/6) F1
foster mothers. Chimeric mice, identified by their Agouti coat color,
were mated with C57BL/6 mice (The Jackson Laboratory, Bar Harbor,
Maine). Germ line transmission was confirmed by the presence of Agouti
coat color in the F1 animals. All Agouti offspring were genotyped by PCR with three primers: E2F (5'-CTT TTA GCA CTT TTT AAG
TCT CTC-3'), E2R (5'-GTT TGC ATT TGC GGG GCA CAG-3'), and IRES4 (5'-GTA
TCT TAT ACA CGT GGC TTT TG-3'). E2F and E2R will amplify the wild-type
allele (118 bp), while E2F and IRES4 will amplify the mutant allele
(500 bp). PCR was performed for 35 cycles of 94°C for 1 min, 56°C
for 30 s, and 68°C for 30 s. For reverse transcription
(RT)-PCR analyses, total cellular RNA was isolated from the thymuses of
heterozygous and wild-type mice by using an Ultraspec RNA isolation
system (Biotecx). Semiquantitative RT-PCR was carried out with a pair
of primers that amplifies the entire muREC2/RAD51L1 cDNA, F1
(5'-CGA AAT GAT CTC TTC CTC CAA AGA-3') and F2 (5'-GAG CAG CAA GAA ACT
AAG ACG AG-3'). To verify the existence of a fusion protein consisting
of muRec2/Rad51L1 and the IRES cassette, RT-PCR was performed on total
RNA from homozygous (8-day gestation [E8.5]
REC2/RAD51L1
/
p53
/
]), heterozygous (thymus), and
wild-type (thymus) embryos, using primers derived from exon 1 and the
IRES cassette, MuREC2A (5'-ATG AGC AGC AAG AAA CTA AGA CGA-3') and
IRES4 (5'-GTA TCT TAT ACA CGT GGC TTT TG-3'), respectively.
Breeding and genotyping.
To genotype the pups resulting from
breeding of chimeric and heterozygous muREC2/RAD51L1
animals, genomic DNA was extracted from the tail tips of 2-week-old
mice by using a QIAamp tissue kit (Qiagen). To genotype by PCR, three
primers were used: E2F, E2R, and IRES4. E2F-E2R will amplify the
wild-type band (118 bp), and E2F-IRES4 will amplify the mutant band
(500 bp). Proper insertion was confirmed by Southern blot analyses of
isolated genomic DNA. The probes and conditions used were the same as
those employed in the initial screening in ES cells.
The
p53-knockout mice (
13) were obtained from The
Jackson Laboratory, and mice heterozygous for both
muREC2/RAD51L1 and
p53 were bred to generate
double-knockout mice. For genotyping,
four primers were used: OIMR013
(5'-CTT GGG TGG AGA GGC TAT TC-3'),
OIMR014 (5'-AGG TGA GAT GAC AGG AGA
TC-3'), OIMR336 (5'-ATA GGT
CGG CGG TTC AT-3'), and OIMR337 (5'-CCC GAG
TAT CTG GAA GAC AG-3').
The optimized protocol for PCR was provided by
Carol Cutler-Linder
of The Jackson
Laboratory.
Histological analysis.
Timed pregnancies were carried out
after mating muREC2/RAD51L1-heterozygous mice and
muREC2/RAD51L1+/
p53+/
mice. Uteri from E5.5, E6.5, E7.5, and
E8.5 pregnancies were isolated in ice-cold phosphate-buffered saline.
Decidua were dissected, fixed overnight in 4% paraformaldehyde,
processed, and embedded in paraffin. Sections were cut at a thickness
of 5 mm, mounted, stained with hematoxylin and eosin (H&E), and
photographed under an Olympus IX50 microscope. To genotype the
sections, embryonic tissues were microdissected out from unstained
paraffin sections. The tissues were lysed, and DNA was extracted for
PCR. The sets of primers that were used for genotyping of pups were employed.
Culture of blastocyst outgrowths.
Pregnant females from
heterozygous intercrosses were sacrificed at E3.5, and blastocysts were
collected by flushing the uteri (12). Blastocysts were
cultured individually in Dulbecco's modified Eagle medium supplemented
with 20% fetal bovine serum (HyClone) in 24-well plates at 37°C in a
5% CO2 incubator. The outgrowths were examined daily and
photographed to monitor their development for 8 to 10 days. Finally,
they were lysed and genotyped by PCR with primers E2F, E2R, and IRES4
(see above).
Generation of double-knockout muREC2/RAD51L1 ES cell
lines.
Two approaches were taken to generate double-knockout ES
cell lines. One was selection of heterozygous ES cells by using high concentrations of G418 (20). Briefly, one correctly targeted ES cell line (E16) was plated on a 6-mm-diameter plate at a density of
106 cells/plate. The cells were selected with G418 at four
different concentrations (0, 1.2 mg/ml, 1.6 mg/ml, and 3.2 mg/ml) for 7 to 8 days. Clones which survived the highest concentration of G418 (3.2 mg/ml) were picked, expanded, and screened by Southern blotting with
probe B. The other strategy involved retargeting the second allele by
using a hygromycin vector. The hygromycin vector was linearized by
XhoI digestion, and 25 µg of vector was electroporated
into heterozygous clones (E16). Hygromycin was added at 200 µg/ml for
a 7- to 8-day selection. Resistant clones were picked and expanded.
Genomic DNA were extracted for screening by Southern blot analysis. The
DNA were digested with XbaI-EcoRV and probed with
probe B (Fig. 1).
 |
RESULTS |
Targeted disruption of the muREC2/RAD51L1 gene.
A
16-kb genomic fragment containing exons 1 and 2 of the
muREC2/RAD51L1 gene was isolated by screening a lambda phage
library from a 129/sv strain mouse genomic library. The genomic
structure was determined by direct sequencing and restriction site
mapping (Fig. 1A). To disrupt the muREC2/RAD51L1 gene, a
3.6-kb EcoRI fragment containing exon 2 was cloned into
pBluescript SK(+). A dicistronic cassette containing an IRES and
-geo was inserted into a unique StuI site in exon 2 (21). The major advantages of this vector are its high
targeting efficiency and its ability to cointegrate with a
histochemically detectable reporter. The use of IRES-
-geo was
particularly appropriate in our case because by RT-PCR,
muREC2/RAD51L1 was found to be actively transcribed in ES
cells (data not shown). The insertion introduced a stop codon,
resulting in a shift of all three reading frames, thus eliminating 83%
of the protein product. The truncated protein lacks important
functional domains such as the A and B box and DNA binding domains,
therefore rendering it nonfunctional. The IRES targeting vector was
linearized and electroporated into J1 ES cells (15). After
G418 selection, 46 clones were picked and expanded. The initial
screening was done with a 500-bp EcoRI fragment (probe B)
outside the vector. DNA was extracted from ES clones and digested with
XbaI. Wild-type clones will produce only one 16-kb band,
while heterozygous clones will generate one mutant band (3 kb) and the
wild-type band (16 kb). Among the 46 clones screened, 28 were found to
contain the disrupted genotype (56.5%). Southern blot analysis, using
probe A on the 5' end (which will produce a 13-kb mutant band and the
16-kb wild-type band), was used to confirm the targeted event (Fig. 1B
and C). The blots were also hybridized with a neo probe to
confirm that only one integration had occurred (data not shown). The
high targeting frequency (56.5%) is due to selection for expression of
the promoterless neo cassette; this eliminates insertions
into introns (random integrations), thus resulting in considerable
enrichment for homologous targeting events.
Phenotype of muREC2/RAD51L1-heterozygous mice.
Two
targeted ES clones were injected into C57BL/6 blastocysts, and seven
high-percentage chimeric mice were obtained (five males and two
females). They were mated with C57BL/6 mice for germ line transmission
of the mutant allele. All of the males and one of the females exhibited
germ line transmission, with one male giving 100% transmission as
judged by the Agouti coat color of its offspring. Heterozygous mice
were phenotypically normal and fertile, with no tumors or other
abnormalities observed, for up to 16 months. To confirm that one allele
had indeed been deleted, Northern and Western blotting was performed on
mRNA and protein from thymuses of both heterozygous and wild-type mice. No signals were seen due to the fact that muREC2/RAD51L1 is
expressed at very low levels in normal tissues. However,
semiquantitative RT-PCR showed that only half of the wild-type level of
mRNA was being expressed in the thymuses of heterozygous mice (Fig.
1D). To verify the fusion between exon 2 and IRES cassette, we designed a pair of primers. The forward primer is on exon 1, and the reverse primer on an IRES-selectable marker. Total RNA was extracted from homozygous embryos, heterozygous mice, and wild-type mice, and RT-PCR
was performed. The results showed that the homozygous and heterozygous
mice contained the fusion transcript while the wild type did not (Fig.
2).

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 2.
RT-PCR for determination of the fusion protein. RT-PCR
was performed with one primer on exon 1 and another primer on the IRES
cassette. Only heterozygous and homozygous samples produced the fusion
product (288 bp).
|
|
muREC2/RAD51L1
/
results in early
embryonic lethality.
Heterozygous mice were interbred, and of the
228 pups genotyped by PCR, 160 were
muREC2/RAD51L1+/
and 68 were wild type,
producing a heterozygous:wild-type ratio of 2.35 to 1. No viable
muREC2/RAD51L1
/
pups were identified,
indicating that homozygosity of the muREC2/RAD51L1 mutation
results in embryonic lethality (see Table 1).
To pinpoint the differences between wild-type and
muREC2/RAD51L1
/
mutant embryos, we next
examined the histology of embryos between
implantation and
gastrulation. Intact decidual swellings obtained
between E5.5 and E8.5
from
muREC2/RAD51L1+/
intercross litters were
fixed, sectioned, and stained with H&E.
Following implantation (E4.5 to
E5.5), abnormalities that distinguished
normal conceptuses from
muREC2/RAD51L1
/
conceptuses could be readily
observed. Wild-type and heterozygous
embryos showed normal growth and
elongation of the egg cylinder,
which contains both embryonic and
extraembryonic ectoderm and
distinct proamniotic cavities (Fig.
3A). In contrast,
muREC2/RAD51L1
/
embryos were smaller in size
and failed to form proamniotic cavities
(Fig.
3E), although they did
display embryonic and extraembryonic
tissues. By E6.5, wild-type
embryos are almost ready for gastrulation,
with the egg cylinders
nearly filling the yolk sac cavity. Elongated
proamniotic and distinct
exocolomic cavities are also well developed
(Fig.
3B). By comparison,
the mutant embryos were 75% smaller
than that of the wild type, cells
were disorganized and started
to degenerate and presumptive areas where
proamniotic cavities
might develop were barely visible (Fig.
3F). By
the time wild-type
embryos undergo gastrulation (E7.5), the mesoderm
develops concomitantly
with the formation of three distinctive
cavities: the amniotic
cavity, yolk sac, and chorionic cavity (Fig.
3C). At this stage,
mutant embryonic tissues almost completely
disappeared and resorption
was evident (Fig.
3G). At E8.5, wild-type
embryos increase tremendously
in size and exhibit formation of more
structures, e.g., the neural
tube and head fold (Fig.
3D). At this
stage, mutant embryos were
dead and were resorbed completely (Fig.
3H).
This type of comparison
was used to generate the data displayed in
Table
1.

View larger version (117K):
[in this window]
[in a new window]
|
FIG. 3.
Histological sections of wild-type and
muREC2/RAD51L1 / embryos grown in utero.
Sagittal sections are shown. All sections were stained with H&E. (A to
D) Wild-type embryos; (E to H)
muREC2/RAD51L1 / embryos. (A) E5.5 wild-type
embryo (early egg cylinder stage). Note the appearance of the
proamniotic cavity and the clearly differentiated embryonic and
extraembryonic ectoderm. (B) E6.5 wild-type embryo (egg cylinder
stage). Note the formation of an exocoelomic cavity and enlargement of
the proamniotic cavity (pac). (C) E7.5 wild-type embryo. The three germ
layers are apparent. The yolk sac (ys), chorion (ch), and amnion (am)
are clearly seen. (D) E8.5 wild-type embryo. More structures are formed
(neural tube [nt], head fold [hf], etc.). (E) E5.5 mutant embryo.
The embryonic region is reduced. No proamniotic cavity is seen. (F)
E6.5 mutant embryo. There is evidence of a great loss of embryonic
tissue and narrowing of the proamniotic cavity. (G) E7.5 mutant embryo.
Only traces of embryonic tissue are left. Resorption is evident
(indicated by the arrow). (H) E8.5 mutant embryo. The embryo is
completely resorbed. The arrows indicate the pac. ec, ectoplacental
cone. Bars, 100 µm.
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Genotypic and phenotypic analysis of the progeny
resulting from intercrosses of
muREC2/RAD51L1-heterozygous micea
|
|
muREC2/RAD51L1
/
blastocysts have a
growth disadvantage in culture.
Blastocysts are composed of two
cell types, pluripotent cells in the inner cell mass (ICM) and
trophectoderm cells. When blastocysts are cultured in vitro, cells from
the ICM proliferate rapidly while cells from the trophectoderm remain
relatively quiescent. Blastocysts (E3.5) from progeny of heterozygous
intercrosses were isolated by uterine flushing and photographed before
and after in vitro culture. Eleven blastocysts which formed a
well-developed epiblast surrounded by epithelial cells and very few
trophoblastic giant cells (Fig. 4A and B)
were found to have either the wild-type or a heterozygous genotype
(Fig. 5). Four appeared smaller and lacked blastocoel cavities (Table 1; Fig. 4C). After 7 days in culture,
those blastocysts showed an impaired outgrowth characterized by a
smaller epiblast outgrowth surrounded by a monolayer of trophoblastic giant cells (Fig. 4D) or no epiblast outgrowth at all; they were genotyped as muREC2/RAD51L1
/
(Fig. 5). All
of these results are consistent with the above-described in vivo
observations of growth retardation in homozygous embryos.

View larger version (108K):
[in this window]
[in a new window]
|
FIG. 4.
Outgrowth of wild-type and
muREC2/RAD51L1 / blastocysts in vitro. The
wild-type blastocyst is larger and has an intact blastocoel cavity (A),
while the mutant blastocyst is smaller and lacks the blastocoel cavity
(C). After 7 days in culture, the wild-type blastocyst grew into a huge
mass characterized by rapid proliferation of the ICM surrounded by
ectodermal cells. (B) Very few trophoblastic giant cells (TG) were seen
(B); however, the growth of mutant blastocyst was greatly retarded. (D)
There were no apparent epiblast outgrowth and few ectodermal cells;
however, trophoblastic giant cells were abundant. Magnifications: ×66
(A and C) and ×33 (B and D).
|
|

View larger version (55K):
[in this window]
[in a new window]
|
FIG. 5.
PCR genotyping of blastocysts and embryos resulting from
muREC2/RAD51L1 interbreeding. DNA were extracted from
blastocysts and embryos ranging from E4.5 to E13.5. PCRs were performed
with probes E2F, E2R, and IRES4 (see Materials and Methods). Wild-type
samples (+/+) produced only one 118-bp band, homozygous samples ( / )
produced one 208-bp band, while heterozygous samples (+/ ) generated
both bands. The marker lane contains a 1-kb DNA ladder.
|
|
muREC2/RAD51L1
/
cells fail to
proliferate in vitro.
To generate muREC2/RAD51L1
double-knockout ES cell lines, we first attempted to target the other
allele by using a hygromycin vector. A hygromycin vector was
constructed by inserting a PGK-hygromycin cassette into the
StuI site of exon 2 (Fig. 1A). The vector was linearized
with XhoI and transfected into a heterozygous ES cell clone
(E16), and a total of 100 clones were picked and expanded. Genomic DNA
were digested with XbaI-EcoRV and probed with
probe B. Wild-type clones produced one 16-kb band, while mutant clones generated a novel 3.3-kb band (Fig. 6A).
Southern blotting showed that six of them were correctly targeted. None
of them were homozygous. As an alternative, we selected heterozygous ES
cells under conditions of elevated G418 concentration (20).
One heterozygous ES clone (E16) was selected with various
concentrations of G418. Forty-eight clones survived at the highest
concentration (3.2 mg/ml). Southern blot analyses with probe B revealed
that none of the clones were homozygous (Fig. 6B). The failure to
obtain any homozygous ES cells is quite statistically significant
(P < 0.01), which strongly suggests that the
muREC2/RAD51L1 gene is required for the viability of ES
cells. These data, coupled with the observation that no homozygous
mutant cells were generated by retargeting or by increasing selective
pressure, make a strong case for the RAD51L1 gene being indispensable for cell growth.

View larger version (52K):
[in this window]
[in a new window]
|
FIG. 6.
Southern blots of products of hygromycin retargeting and
G418 selection. (A) Hygromycin retargeting. DNA was digested with
XbaI and EcoRV and then probed with probe B. Nontargeted clones (+/ ) produced one 16-kb band (middle two lanes).
Heterozygous clones (+/h) generated one 16-kb wild-type band and one
3.3-kb mutant band (two outside lanes) because the hygromycin cassette
introduced a new EcoRV site. (B) G418 selection. DNA was
digested with XbaI and then probed with probe B (Fig. 1).
All of the clones produced two bands (16-kb wild-type and 3-kb mutant
bands), indicating that they were still heterozygous.
|
|
Early embryonic lethality is partially rescued by p53.
p53
plays a pivotal role in cell cycle control and apoptosis, and the
embryonic lethality caused by mRAD51, BRCA1, and BRCA2 is partially
rescued while mdm2-deficient mice are completely rescued in a
p53-null background (9, 16, 17, 19). To explore
the possibility of rescue by p53,
muREC2/RAD51L1+/
mice were crossed with
p53-knockout mice. One hundred seventy pups from
double-heterozygous crosses (muREC2/RAD51L1+/
p53+/
× muREC2/RAD51L1+/
p53+/
were genotyped by PCR. None of them were
homozygous for muREC2/RAD51L1, indicating that the lethal
phenotype could not be rescued completely in a p53-null
background. Twenty E7.5, 40 E8.5, and 30 E9.5 embryos from progeny of
double-heterozygous crosses were isolated and genotyped by PCR.
Interestingly, one E7.5 embryo, two E8.5 embryos, and one E9.5 embryo
were homozygous for both muREC2/RAD51L1 and p53
(Table 2). No homozygous mutant
muREC2/RAD51L1 mice were identified in either a wild-type or
heterozygous p53 background, indicating that p53
heterozygosity was insufficient to rescue the embryonic-lethal
phenotype. Double-mutant embryos appeared grossly smaller than their
normal counterparts (Fig. 7).
Histological studies of one E7.5 double mutant showed that some normal
structures were formed
for example, chorion cavities; however,
structures such as yolk sacs and amniotic cavities were missing. Cells
in the embryos also looked abnormal (Fig. 7B). Compared with the muREC2/RAD51L1
/
embryos in a wild-type
p53 or p53-heterozygous background, double mutants demonstrated significantly advanced proliferation and development.
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Genotyping of progeny resulting from crosses between
muREC2/RAD51L1+/
p53+/ and
muREC2/RAD51L1+/
p53+/ mice
|
|

View larger version (84K):
[in this window]
[in a new window]
|
FIG. 7.
Histological sections of
muREC2/RAD51L1+/
p53+/ (A) and
muREC2/RAD51L1 /
p53 / (B) embryos grown in utero to E7.5.
Sagittal sections are shown. All sections were stained with H&E. (A) In
double-heterozygous embryos, typical three chambers were observed, with
formation of the chorion (ch), yolk sac (ys), and amnion (am). (B) The
double-mutant embryo was smaller in size, and the chambers were not
distinguishable. Although the ectoplacental cone (ec) is present, other
structures cannot be identified, and embryonic cells looked
morphologically abnormal. Bars, 100 µm.
|
|
 |
DISCUSSION |
In this study, we have generated a muREC2/RAD51L1
knockout by homologous recombination. Heterozygous mice were viable and looked normal; however, interbreeding of heterozygous mice failed to
generate viable pups, indicating embryonic lethality. Timed pregnancies
showed that mutant embryos died at approximately E5.5 to E6.5, and
blastocyst outgrowth was also hindered in mutant embryos.
Interestingly, muREC2/RAD51L1 mutant embryos survived longer
(E8.5 to E9.5) and developed further in a p53-mutant background.
These findings show striking parallels with previous work on
RAD51-, BRCA1-, and BRCA2-knockout
mice. Both RAD51- and BRCA1-mutant embryos die
before E7.5, while BRCA2-mutant embryos survive longer (E8.5
to E9.5) (9, 16, 17, 23, 30, 33). All of them exhibit
reduced cellular proliferation, and the early lethality can be
partially rescued by p53.
The phenotypic similarities shared by RAD51,
BRCA1, BRCA2, and REC2/RAD51L1 mutants
strongly suggest that these genes act together in some of the most
important processes in a cell, e.g., DNA repair, transcription, and
cell cycle control. Efficient repair of DNA damage is crucial to
maintaining the integrity of the genome and, thereby, the survival of
the cell or organism. Our current understanding of double-strand break
(DSB) DNA repair is derived primarily from studies of bacteria and
yeast. In Saccharomyces cerevisiae, Rad51 (a homolog of
RecA) has been shown to interact with Rad52, Rad55, and replication
protein A (6, 11, 18). Rad55 in turn interacts with Rad57,
and a Rad55-Rad57 complex exhibits ATPase activity and promotes strand
exchange mediated by Rad51 (14, 29). It is believed that
together replication protein A, Rad52, Rad51, Rad55, and Rad57 assemble
at the site of a DSB, forming a huge complex called a recombinosome
which pulls the two ends of the DSB together and repairs the damage (11).
At the heart of this process is the activity of the RAD51
gene product. It is believed that Rad51 acts to conjoin the DNA during
the repair event, providing a recombinational aspect of the process.
Although this activity is crucial for repair of damaged DNA, the fact
that it is essential for early embryonic life is somewhat puzzling. Our
data suggest that the RAD51 analogue REC2/RAD51L1 is also an essential gene, since homozygous knockouts exhibit an
embryonic-lethal phenotype. Interestingly, we have not been able to
detect in vitro recombination activities, similar to those of Rad51
(29), mediated by Rec2/Rad51L1. Since hsRec2/Rad51L1 has
been shown to interact directly with a related member of the Rad51
family, Rad51C (4), and Rad51C interacts with Rad51 (as judged by the yeast two-hybrid system), the loss of hsRec2/Rad51L1 may,
in turn, lead to dysfunctional-complex formation. The activity of such
a complex is likely to be similar to that of the recombinosome of
S. cerevisiae (7) (see also reference
27 and references cited therein) which is
responsible for DNA repair. Hence, it is possible that hsRec2/Rad51L1
performs a regulatory function within a complex that directs the repair
of damaged DNA or monitors the accuracy of DNA replication events. If
the complex were not properly formed, the cell would lack the capacity
to monitor replication errors and, by extension, enable the propagation
of genetic mutations. The activity of this protein may also be distinct
from that of the so-called complex. In fact, Thacker (32)
does not include this protein as part of the group of repair proteins
(Rad51, Rad52, etc.) that act at the site of damage. He speculates that
the Rec2/Rad51L1 protein could act more as a regulator of the repair
process, and our data align with this notion. Since the overexpression
of hRac2/hRad51L1 has been shown to reduce the cell cycle rate
(10), we speculate that the protein functions at the level
of DNA replication, expanding the window of time in which repair can
take place. Close examination of the data of Havre et al.
(10) data reveals that, in fact, S phase becomes elongated
as a function of increased levels of this protein. This hypothesis is
supported by recent evidence that disruption of another mouse
RAD51-like gene, RAD51d, causes an
early-embryonic-lethal phenotype (26a). We have recently
demonstrated that hRec2/Rad51L1 is a protein kinase (9a), an
activity that fits well with such a proposed role.
 |
ACKNOWLEDGMENTS |
We thank Peter Mountford for sending us the IRES cassette and
Sigrid Swagemakers for the pPGK-Hygro vector. We are grateful to
members of the Kmiec laboratory for helpful discussions and to Thomas
Knudson and Leslie Lock (Thomas Jefferson University) for evaluation of
embryonic development stages.
This work was supported by NIH grant R01 HL-58563-01A1.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Biological Sciences, Wolf Hall, University of Delaware, Newark, DE
19716. Phone: (302) 831-3221. Fax: (302) 831-8786. E-mail:
ekmiec{at}udel.edu.
 |
REFERENCES |
| 1.
|
Albala, J. S.,
M. P. Thelen,
C. Prange,
W. Fan,
M. Christensen,
L. H. Thompson, and G. G. Lennon.
1997.
Identification of a novel human RAD51 homolog, RAD51B.
Genomics
46:476-479[Medline].
|
| 2.
|
Buchhop, S.,
M. K. Gibson,
X. W. Wang,
P. Wagner,
H. W. Sturzbecher, and C. C. Harris.
1997.
Interaction of p53 with the human Rad51 protein.
Nucleic Acids Res.
25:3868-3874[Abstract/Free Full Text].
|
| 3.
|
Cartwright, R.,
A. M. Dunn,
P. J. Simpson,
C. E. Tambini, and J. Thacker.
1998.
Isolation of novel human and mouse genes of the recA/RAD51 recombination-repair gene family.
Nucleic Acids Res.
26:1653-1659[Abstract/Free Full Text].
|
| 4.
|
Dosanjh, M. K.,
D. W. Collins,
W. Fan,
G. G. Lennon,
J. S. Albala,
Z. Shen, and D. Schild.
1998.
Isolation and characterization of RAD51C, a new human member of the RAD51 family of related genes.
Nucleic Acids Res.
26:1179-1184[Abstract/Free Full Text].
|
| 5.
|
Essers, J.,
R. W. Hendriks,
S. M. Swagemakers,
C. Troelstra,
J. de Wit,
D. Bootsma,
J. H. Hoeijmakers, and R. Kanaar.
1997.
Disruption of mouse RAD54 reduces ionizing radiation resistance and homologous recombination.
Cell
89:195-204[Medline].
|
| 6.
|
Firmenich, A. A.,
M. Elias-Arnanz, and P. Berg.
1995.
A novel allele of Saccharomyces cerevisiae RFA1 that is deficient in recombination and repair and suppressible by RAD52.
Mol. Cell. Biol.
15:1620-1631[Abstract].
|
| 6a.
| Gamper, H. Unpublished observations.
|
| 7.
|
Golub, E. I.,
O. V. Kovalenko,
R. C. Gupta,
D. C. Ward, and C. M. Radding.
1997.
Interaction of human recombination proteins Rad51 and Rad54.
Nucleic Acids Res.
25:4106-4110[Abstract/Free Full Text].
|
| 8.
|
Haaf, T.,
E. I. Golub,
G. Reddy,
C. M. Radding, and D. C. Ward.
1995.
Nuclear foci of mammalian Rad51 recombination protein in somatic cells after DNA damage and its localization in synaptonemal complexes.
Proc. Natl. Acad. Sci. USA
92:2298-2302[Abstract/Free Full Text].
|
| 9.
|
Hakem, R.,
J. L. de la Pompa,
A. Elia,
J. Potter, and T. W. Mak.
1997.
Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation.
Nat. Genet.
16:298-302[Medline].
|
| 9a.
| Havre, P., M. Rice, R. Ramos, and E. B. Kmiec.
HsRec2/Rad51L1, a protein influencing cell cycle progression, has
protein kinase activity. Exp. Cell Res., in press.
|
| 10.
|
Havre, P. A.,
M. C. Rice,
A. Nöe, and E. B. Kmiec.
1998.
The human REC2/RAD51B gene acts as a DNA damage sensor by inducing G1 delay and hypersensitivity to UV irradiation.
Cancer Res.
58:4733-4739[Abstract/Free Full Text].
|
| 11.
|
Hays, S. L.,
A. A. Firmenich, and P. Berg.
1995.
Complex formation in yeast double-strand break repair: participation of Rad51, Rad52, Rad55, and Rad57 proteins.
Proc. Natl. Acad. Sci. USA
92:6925-6929[Abstract/Free Full Text].
|
| 12.
|
Hogan, B.,
R. Beddington,
F. Constantini, and E. Lacy.
1994.
Manipulating the mouse embryo.
Cold Spring Harbor Laboratory Press, Plainview, N.Y
|
| 13.
|
Jacks, T.,
L. Remington,
B. O. Williams,
E. M. Schmitt,
S. Halachmi,
R. T. Bronson, and R. A. Weinberg.
1994.
Tumor spectrum analysis in p53-mutant mice.
Curr. Biol.
4:1-7[Medline].
|
| 14.
|
Johnson, R. D., and L. S. Symington.
1995.
Functional differences and interactions among the putative RecA homologs Rad51, Rad55, and Rad57.
Mol. Cell. Biol.
15:4843-4850[Abstract].
|
| 15.
|
Li, E.,
T. H. Bestor, and R. Jaenisch.
1992.
Targeted mutation of the DNA methyltransferase gene results in embryonic lethality.
Cell
69:915-926[Medline].
|
| 16.
|
Lim, D. S., and P. Hasty.
1996.
A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53.
Mol. Cell. Biol.
16:7133-7143[Abstract].
|
| 17.
|
Ludwig, T.,
D. L. Chapman,
V. E. Papaioannou, and A. Efstratiadis.
1997.
Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos.
Genes Dev.
11:1226-1241[Abstract/Free Full Text].
|
| 18.
|
Milne, G. T., and D. T. Weaver.
1993.
Dominant negative alleles of RAD52 reveal a DNA repair/recombination complex including RAD51 and RAD52.
Genes Dev.
7:1755-1765[Abstract/Free Full Text].
|
| 19.
|
Montes de Oca Luna, R.,
D. S. Wagner, and G. Lozano.
1995.
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53.
Nature
378:203-206[Medline].
|
| 20.
|
Mortensen, R. M.,
D. A. Conner,
S. Chao,
A. A. T. Geisterfer-Lowrance, and J. G. Seidman.
1992.
Production of homozygous mutant ES cells with a single targeting construct.
Mol. Cell. Biol.
12:2391-2395[Abstract/Free Full Text].
|
| 21.
|
Mountford, P.,
B. Zevnik,
A. Duwel,
J. Nichols,
M. Li,
C. Dani,
M. Robertson,
I. Chambers, and A. Smith.
1994.
Dicistronic targeting constructs: reporters and modifiers of mammalian gene expression.
Proc. Natl. Acad. Sci. USA
91:4303-4307[Abstract/Free Full Text].
|
| 22.
|
Peng, L.,
M. C. Rice, and E. B. Kmiec.
1998.
Analysis of the human RAD51L1 promoter region and its activation by UV light.
Genomics
54:529-541[Medline].
|
| 23.
|
Pentchev, P. G.,
M. T. Vanier,
K. Suzuki, and M. C. Patterson.
1995.
The metabolic and molecular basis of inherited diseases.
McGraw-Hill, Philadelphia, Pa
|
| 24.
|
Pittman, D. L.,
L. R. Weinberg, and J. C. Schimenti.
1998.
Identification, characterization, and genetic mapping of Rad51d, a new mouse and human RAD51/RecA-related gene.
Genomics
49:103-111[Medline].
|
| 24a.
| Rice, M. Unpublished observations.
|
| 25.
|
Rice, M. C.,
S. T. Smith,
F. Bullrich,
P. A. Havre, and E. B. Kmiec.
1997.
Isolation of human and mouse genes based on homology to REC2, a recombinational repair gene from the fungus Ustilago maydis.
Proc. Natl. Acad. Sci. USA
94:7417-7422[Abstract/Free Full Text].
|
| 26.
|
Rubin, B. P.,
D. O. Ferguson, and W. K. Holloman.
1994.
Structure of REC2, a recombinational repair gene of Ustilago maydis, and its function in homologous recombination between plasmid and chromosomal sequences.
Mol. Cell. Biol.
14:6287-6296[Abstract/Free Full Text].
|
| 26a.
| Schimenti, J. Personal communication.
|
| 27.
|
Shen, Z.,
P. E. Pardington-Purtymun,
J. C. Comeaux,
R. K. Moyzis, and D. J. Chen.
1996.
UBL1, a human ubiquitin-like protein associating with human RAD51/RAD52 proteins.
Genomics
36:271-279[Medline].
|
| 27a.
| Shu, Z., et al. Submitted for publication.
|
| 28.
|
Sturzbecher, H. W.,
B. Donzelmann,
W. Henning,
U. Knippschild, and S. Buchhop.
1996.
p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction.
EMBO J.
15:1992-2002[Medline].
|
| 29.
|
Sung, P.
1997.
Function of yeast Rad52 protein as a mediator between replication protein A and the Rad51 recombinase.
J. Biol. Chem.
272:28194-28197[Abstract/Free Full Text].
|
| 30.
|
Suzuki, A.,
J. L. de la Pompa,
R. Hakem,
A. Elia,
R. Yoshida,
R. Mo,
H. Nishina,
T. Chuang,
A. Wakeham,
A. Itie,
W. Koo,
P. Billia,
A. Ho,
M. Fukumoto,
C. C. Hui, and T. W. Mak.
1997.
Brca2 is required for embryonic cellular proliferation in the mouse.
Genes Dev.
11:1242-1252[Abstract/Free Full Text].
|
| 31.
|
Tebbs, R. S.,
Y. Zhao,
J. D. Tucker,
J. B. Scheerer,
M. J. Siciliano,
M. Hwang,
N. Liu,
R. J. Legerski, and L. H. Thompson.
1995.
Correction of chromosomal instability and sensitivity to diverse mutagens by a cloned cDNA of the XRCC3 DNA repair gene.
Proc. Natl. Acad. Sci. USA
92:6354-6358[Abstract/Free Full Text].
|
| 32.
|
Thacker, J.
1999.
A surfeit of RAD51-like genes?
Trends Genet.
15:166-168[Medline].
|
| 33.
|
Thompson, A.,
Y. Zhang,
D. Kamen,
C. W. Jackson,
R. D. Cardiff, and K. Ravid.
1996.
Deregulated expression of c-myc in megakaryocytes of transgenic mice increases megakaryopoiesis and decreases polyploidization.
J. Biol. Chem.
271:22976-22982[Abstract/Free Full Text].
|
| 34.
|
Tsuzuki, T.,
Y. Fujii,
K. Sakumi,
Y. Tominaga,
K. Nakao,
M. Sekiguchi,
A. Matsushiro,
Y. Yoshimura, and T. Morita.
1996.
Targeted disruption of the Rad51 gene leads to lethality in embryonic mice.
Proc. Natl. Acad. Sci. USA
93:6236-6240[Abstract/Free Full Text].
|
Molecular and Cellular Biology, December 1999, p. 8686-8693, Vol. 19, No. 12
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Kuznetsov, S. G., Haines, D. C., Martin, B. K., Sharan, S. K.
(2009). Loss of Rad51c Leads to Embryonic Lethality and Modulation of Trp53-Dependent Tumorigenesis in Mice. Cancer Res.
69: 863-872
[Abstract]
[Full Text]
-
Kuznetsov, S., Pellegrini, M., Shuda, K., Fernandez-Capetillo, O., Liu, Y., Martin, B. K., Burkett, S., Southon, E., Pati, D., Tessarollo, L., West, S. C., Donovan, P. J., Nussenzweig, A., Sharan, S. K.
(2007). RAD51C deficiency in mice results in early prophase I arrest in males and sister chromatid separation at metaphase II in females. JCB
176: 581-592
[Abstract]
[Full Text]
-
Liu, Y., Tarsounas, M., O'Regan, P., West, S. C.
(2007). Role of RAD51C and XRCC3 in Genetic Recombination and DNA Repair. J. Biol. Chem.
282: 1973-1979
[Abstract]
[Full Text]
-
Date, O., Katsura, M., Ishida, M., Yoshihara, T., Kinomura, A., Sueda, T., Miyagawa, K.
(2006). Haploinsufficiency of RAD51B Causes Centrosome Fragmentation and Aneuploidy in Human Cells.. Cancer Res.
66: 6018-6024
[Abstract]
[Full Text]
-
Hinz, J. M., Tebbs, R. S., Wilson, P. F., Nham, P. B., Salazar, E. P., Nagasawa, H., Urbin, S. S., Bedford, J. S., Thompson, L. H.
(2006). Repression of mutagenesis by Rad51D-mediated homologous recombination. Nucleic Acids Res
34: 1358-1368
[Abstract]
[Full Text]
-
Proudfoot, C., McCulloch, R.
(2005). Distinct roles for two RAD51-related genes in Trypanosoma brucei antigenic variation. Nucleic Acids Res
33: 6906-6919
[Abstract]
[Full Text]
-
Abe, K., Osakabe, K., Nakayama, S., Endo, M., Tagiri, A., Todoriki, S., Ichikawa, H., Toki, S.
(2005). Arabidopsis RAD51C Gene Is Important for Homologous Recombination in Meiosis and Mitosis. Plant Physiol.
139: 896-908
[Abstract]
[Full Text]
-
Smiraldo, P. G., Gruver, A. M., Osborn, J. C., Pittman, D. L.
(2005). Extensive Chromosomal Instability in Rad51d-Deficient Mouse Cells. Cancer Res.
65: 2089-2096
[Abstract]
[Full Text]
-
Miller, K. A., Sawicka, D., Barsky, D., Albala, J. S.
(2004). Domain mapping of the Rad51 paralog protein complexes. Nucleic Acids Res
32: 169-178
[Abstract]
[Full Text]
-
Deng, C.-X., Wang, R.-H.
(2003). Roles of BRCA1 in DNA damage repair: a link between development and cancer. Hum Mol Genet
12: R113-123
[Abstract]
[Full Text]
-
Yokoyama, H., Kurumizaka, H., Ikawa, S., Yokoyama, S., Shibata, T.
(2003). Holliday Junction Binding Activity of the Human Rad51B Protein. J. Biol. Chem.
278: 2767-2772
[Abstract]
[Full Text]
-
Symington, L. S.
(2002). Role of RAD52 Epistasis Group Genes in Homologous Recombination and Double-Strand Break Repair. Microbiol. Mol. Biol. Rev.
66: 630-670
[Abstract]
[Full Text]
-
Godthelp, B. C., Wiegant, W. W., van Duijn-Goedhart, A., Scharer, O. D., van Buul, P. P. W., Kanaar, R., Zdzienicka, M. Z.
(2002). Mammalian Rad51C contributes to DNA cross-link resistance, sister chromatid cohesion and genomic stability. Nucleic Acids Res
30: 2172-2182
[Abstract]
[Full Text]
-
van den Bosch, M., Zonneveld, J. B. M., Vreeken, K., de Vries, F. A. T., Lohman, P. H. M., Pastink, A.
(2002). Differential expression and requirements for Schizosaccharomyces pombeRAD52 homologs in DNA repair and recombination. Nucleic Acids Res
30: 1316-1324
[Abstract]
[Full Text]
-
Wiese, C., Collins, D. W., Albala, J. S., Thompson, L. H., Kronenberg, A., Schild, D.
(2002). Interactions involving the Rad51 paralogs Rad51C and XRCC3 in human cells. Nucleic Acids Res
30: 1001-1008
[Abstract]
[Full Text]
-
Liu, N., Schild, D., Thelen, M. P., Thompson, L. H.
(2002). Involvement of Rad51C in two distinct protein complexes of Rad51 paralogs in human cells. Nucleic Acids Res
30: 1009-1015
[Abstract]
[Full Text]
-
Masson, J.-Y., Tarsounas, M. C., Stasiak, A. Z., Stasiak, A., Shah, R., McIlwraith, M. J., Benson, F. E., West, S. C.
(2001). Identification and purification of two distinct complexes containing the five RAD51 paralogs. Genes Dev.
15: 3296-3307
[Abstract]
[Full Text]
-
Fojo, T.
(2001). Cancer, DNA Repair Mechanisms, and Resistance to Chemotherapy. JNCI J Natl Cancer Inst
93: 1434-1436
[Full Text]
-
Vasquez, K. M., Marburger, K., Intody, Z., Wilson, J. H.
(2001). Manipulating the mammalian genome by homologous recombination. Proc. Natl. Acad. Sci. USA
98: 8403-8410
[Abstract]
[Full Text]
-
Masson, J.-Y., Stasiak, A. Z., Stasiak, A., Benson, F. E., West, S. C.
(2001). Complex formation by the human RAD51C and XRCC3 recombination repair proteins. Proc. Natl. Acad. Sci. USA
98: 8440-8446
[Abstract]
[Full Text]
-
Takata, M., Sasaki, M. S., Sonoda, E., Fukushima, T., Morrison, C., Albala, J. S., Swagemakers, S. M. A., Kanaar, R., Thompson, L. H., Takeda, S.
(2000). The Rad51 Paralog Rad51B Promotes Homologous Recombinational Repair. Mol. Cell. Biol.
20: 6476-6482
[Abstract]
[Full Text]
-
Schild, D., Lio, Y.-c., Collins, D. W., Tsomondo, T., Chen, D. J.
(2000). Evidence for Simultaneous Protein Interactions between Human Rad51 Paralogs. J. Biol. Chem.
275: 16443-16449
[Abstract]
[Full Text]
-
O'Regan, P., Wilson, C., Townsend, S., Thacker, J.
(2001). XRCC2 Is a Nuclear RAD51-like Protein Required for Damage-dependent RAD51 Focus Formation without the Need for ATP Binding. J. Biol. Chem.
276: 22148-22153
[Abstract]
[Full Text]